News coverage about Sophiris Bio (NASDAQ:SPHS) has trended somewhat positive on Wednesday, according to Accern Sentiment. The research firm identifies positive and negative news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Sophiris Bio earned a news sentiment score of 0.15 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 45.2947579172714 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Several equities analysts recently issued reports on SPHS shares. Rodman & Renshaw reiterated a “buy” rating and set a $6.00 price target on shares of Sophiris Bio in a research report on Thursday, June 1st. Maxim Group set a $6.00 price target on shares of Sophiris Bio and gave the company a “buy” rating in a research report on Thursday, June 8th. HC Wainwright set a $6.00 price target on shares of Sophiris Bio and gave the company a “buy” rating in a research report on Friday, August 11th. Finally, ValuEngine cut shares of Sophiris Bio from a “hold” rating to a “sell” rating in a research report on Tuesday, June 13th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $6.60.
Shares of Sophiris Bio (SPHS) traded up 4.15% during trading on Wednesday, hitting $2.26. 329,639 shares of the company traded hands. The company’s market capitalization is $68.05 million. The company has a 50 day moving average price of $1.99 and a 200 day moving average price of $2.33. Sophiris Bio has a 52 week low of $1.80 and a 52 week high of $3.48.
ILLEGAL ACTIVITY NOTICE: “Sophiris Bio (SPHS) Receives Daily Media Impact Score of 0.15” was first published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://stocknewstimes.com/2017/09/13/sophiris-bio-sphs-receives-daily-media-impact-score-of-0-15.html.
Sophiris Bio Company Profile
Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).
Receive News & Ratings for Sophiris Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.